Form 4: Aclaris CFO's Stock Transactions Post RSU Vesting
Insider Transaction Report
Aclaris Therapeutics' CFO, Kevin Balthaser, reported recent acquisitions of common stock through RSU vesting and subsequent dispositions for tax obligations.
Summary
- Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics, Inc. (ACRS), reported changes in his beneficial ownership of common stock.
- On December 31, 2025, he acquired 73,750 shares of common stock through the vesting of restricted stock units (RSUs) and subsequently disposed of 19,934 shares at a price of $3.01 per share to satisfy tax withholding obligations.
- On January 1, 2026, he acquired 7,500 shares of common stock from RSU vesting and disposed of 2,250 shares at a price of $3.01 per share for tax withholding.
- On January 2, 2026, he acquired 13,200 shares of common stock from RSU vesting and disposed of 4,461 shares at a price of $2.88 per share for tax withholding.
- Following these reported transactions, Kevin Balthaser's direct beneficial ownership of Aclaris Therapeutics common stock stands at 160,413 shares.
Sentiment
Score: 5
Explanation: Neutral. This is a routine insider transaction report detailing RSU vesting and tax-related share dispositions, which are standard compensation events and do not inherently indicate positive or negative company performance or outlook.
Positives
- The CFO continues to hold a significant number of shares (160,413), indicating alignment of executive interests with shareholder value.
- The vesting of restricted stock units represents a planned and routine compensation event for the executive, reflecting the company's equity incentive program.
Negatives
- The disposition of shares for tax withholding, while a standard practice, results in a reduction of the executive's direct share ownership.
Future Outlook
The filing details future vesting schedules for restricted stock units, indicating continued equity compensation for the Chief Financial Officer through at least January 2027, subject to continuous service.
Industry Context
This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It reflects standard executive compensation practices involving equity awards and subsequent tax-related share dispositions, rather than strategic industry moves or specific company performance indicators.
Comparison to Industry Standards
- The RSU vesting and subsequent tax-related share dispositions are standard practices for executive compensation in publicly traded companies across various industries.
- The specific number of shares and their value are particular to Aclaris Therapeutics and its compensation structure for its CFO, Kevin Balthaser. This filing does not provide specific comparable companies, projects, or results for a detailed industry benchmark comparison.
Stakeholder Impact
- Shareholders: Provides transparency into executive stock ownership and compensation, aligning executive interests with shareholder value through equity awards.
- Employees: Reflects standard executive compensation practices, which can influence broader compensation strategies within the company.
Next Steps
- Future vesting of the final installment of 7,500 RSUs on January 1, 2027, subject to continuous service.
- Future vesting of the remaining 34% of 13,200 RSUs on January 2, 2027, subject to continuous service.
Key Dates
| Date | Description |
|---|---|
| 2023-01-01 | Grant date for 7,500 RSUs, which vest in four equal installments on the first, second, third, and fourth anniversaries. |
| 2024-12-31 | Vesting date for 50% of the 73,750 restricted stock units. |
| 2025-01-02 | Vesting date for 33% of the 13,200 restricted stock units. |
| 2025-12-31 | Transaction date for the acquisition of 73,750 shares and disposition of 19,934 shares for tax withholding. |
| 2025-12-31 | Vesting date for the remaining 50% of the 73,750 restricted stock units. |
| 2026-01-01 | Transaction date for the acquisition of 7,500 shares and disposition of 2,250 shares for tax withholding. |
| 2026-01-02 | Transaction date for the acquisition of 13,200 shares and disposition of 4,461 shares for tax withholding. |
| 2026-01-02 | Vesting date for 33% of the 13,200 restricted stock units. |
| 2026-01-05 | Signature date of the Form 4 filing. |
| 2027-01-01 | Future vesting date for the final installment of the 7,500 restricted stock units. |
| 2027-01-02 | Future vesting date for the remaining 34% of the 13,200 restricted stock units. |
Keywords
Aclaris Therapeutics, ACRS, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Kevin Balthaser, CFO, Stock Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.